SPAG5 and breast carcinoma: A previous study indicated that high SPAG5 expression in breast cancer patients was an independent predictor of an increased proportion of pathological complete response after receiving a combined cytotoxic chemotherapy, because SPAG5 (Ch17q11.2) is located at CEP17, which is a marker of chromosomal instability and linked to anthracycline sensitivity [7].